Vivid Seats (NASDAQ:SEAT) 주식

VIVID SEATS INC - CLASS A

Vivid Seats

Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.

Stocks Photo by Jirapong Manustrong on Shutterstock

Analyst Color

Analyst Ratings

Trading Ideas

AMZN

DASH

GOOG

GOOGL

PINS

SEAT

UBER

뱅크오브아메리카(Bank of America)의 새 보고서는 2024년 하반기에 100개가 넘는 촉발제를 강조한다. 이 보고서는 주요 지수가 사상 최고치에 가까워지면서 투자자들이 집중해야 할 주요 이벤트와 주식들에 주목한다.

아마존, 핀터레스트, 웨이페어는 BofA가 2024년 하반기에 주목해야 할 주식 7종목의 상위

Vivid Seats Inc

SeaTwirl AB

SEATECH VENTURES CORP by SEATECH VENTURES CORP.

Seatech Ventures Corp

Seatrium Ltd

SEATRIUM LTD UNSP/ADR by Seatrium Limited

Seatrium Ltd ADR

<a href="https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor" title="https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor">https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor</a>

Biotech

News

General

'FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies; Agency determines the safety and effectiveness of these immunotherapies can be assured without a REMS' - FDA

<a href="https://www.youtube.com/watch?v=nWcpp2YU6xk">https://www.youtube.com/watch?v=nWcpp2YU6xk</a>
&nbsp;

Macro Economic Events

Politics

Global

Economics

Market Vectors Rare Earth/Strategic Metals Etf

REMX

President Trump Says Will Do Official Meeting With African Union In July; Trump's Africa Envoy Says Negotiating Mineral Deal With Congo And Looking At Deals With Rwanda And Supporting Lobito Corridor

WIIM

PLRX

Pliant Therapeutics shares are trading higher. The company announced the voluntary discontinuation of BEACON-IPF.

Offerings

GCMG

GCM Grosvenor Files For Mixed Shelf Of Up To $350M

<a href="https://www.bloomberg.com/news/articles/2025-06-27/ford-forced-to-idle-multiple-us-plants-on-china-magnet-shortage?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-27/ford-forced-to-idle-multiple-us-plants-on-china-magnet-shortage?embedded-checkout=true</a>

'Ford Forced to Idle Multiple US Plants on China Magnet Shortage'- Bloomberg

With news breaking earlier this morning that the U.S. and China have <a href="https://www.benzinga.com/news/politics/25/06/46133537/howard-lutnick-confirms-us-china-trade-agreement-reaffirms-white-houses-progress-to-close-deals-with-10-other-trading-partners">finalized a trade understanding</a>, the major equity indices bounced higher on Friday. However, Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) suffered a conspicuous decline. While controversial in some circles because of its obvious ties to President Donald Trump, the media company's Truth Social platform will likely be relevant for at least the next three years. As such, DJT stock could be a compelling idea.
Undoubtedly, exposure to Trump Media is risky. Since the start of the year, DJT stock hemorrhaged about 49% of market value. Over the past 52 weeks, the security is down more than 52% at time of writing. However, it's also undeniable that DJT commands <a href="https://www.benzinga.com/m-a/24/03/37943780/exclusive-trump-media-company-goes-public-financial-experts-say-djt-a-meme-stock-this-is-going-to-be">meme-like qualities</a>. With the tremendous popularity of the Trump brand, the company that bears the president's name might not stay deflated indefinitely.
Whether one agrees with his politics or not, Trump has scored multiple victories. As stated earlier, his administration reached an agreement with Chinese diplomats. Among the key components of the trade agreement is China's commitment to supply rare earths, which represent critical commodities that undergird a wide array of products. Further, the negotiated terms indicate that there's a method to the madness, thereby instilling confidence in the president's leadership.
Another big win stemmed from U.S. forces striking key Iranian nuclear sites, which quickly led to a <a href="https://www.benzinga.com/markets/equities/25/06/46090358/us-stocks-likely-to-edge-higher-as-iran-israel-ceasefire-holds-micron-technology-general-mills-in-focus-ahead-of-earnings">ceasefire between Iran and Israel</a>. While the cessation of hostilities remains a fragile agreement, that the two sides have been willing to negotiate is nonetheless a massive political success for Trump. As the Cato Institute pointed out, Americans don't want to be <a href="https://www.cato.org/blog/americans-dont-want-another-war-middle-east">dragged</a> into another war in the Middle East. The use of force could have ended badly but didn't.
Even on the domestic front, Trump is winning. Just recently, The New York Times reported that the University of Virginia President James E. Ryan has stepped down due to <a href="https://www.nytimes.com/2025/06/27/us/politics/uva-president-resigns-jim-ryan-trump.html">pressure</a> from the Trump administration. Through the resignation, the academic institution will be able to help resolve a Justice Department inquiry regarding its diversity, equity and inclusion initiatives.
With Trump being emboldened by his successes, he could potentially become even more aggressive with his policies, thereby providing fuel for Truth Social.
<h2 class="wp-block-heading">Making A Technical And Statistical Case For DJT Stock</h2>
While the fundamental narrative may be attractive for DJT stock, at the end of the day, investors must be willing to buy the security. From the perspective of technical analysis, it's possible that DJT has reached — or is close to reaching — a support level. Again, given its meme-like qualities, the market may perceive the red ink as a discount.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="1000" height="596" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27152138/DJT-stock-technical-analysis.jpg" alt="" class="wp-image-965382" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27152138/DJT-stock-technical-analysis.jpg 1000w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27152138/DJT-stock-technical-analysis-300x179.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27152138/DJT-stock-technical-analysis-768x458.jpg 768w" sizes="(max-width: 1000px) 100vw, 1000px" /><figcaption class="wp-element-caption">Image by TradingView</figcaption></figure>
Still, the above represents a heuristic statement: DJT stock appears to have hit support because of the impact of an imaginary horizontal line. Technical analysts will often argue that support represents clusters of buy orders but the logic behind this is generally unsubstantiated.
Rather than assume the existence of buy orders — which is a presuppositional fallacy — I prefer empirically analyzing market demand. But in order to conduct such an analysis, the underlying dataset (the share price history of DJT stock) must speak a uniform language. As such, I convert the share price history into market breadth, which is the sequence of accumulative and distributive sessions.
At the moment, the price action of DJT stock can be converted as a "2-8-D" sequence: two up weeks, eight down weeks, with a negative trajectory across the 10-week period. Admittedly, this conversion process compresses DJT's magnitude dynamism into a simple binary code. However, binary codes are, by definition, discrete events, meaning that their boundaries are defined.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27152118/DJT-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-965381" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27152118/DJT-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27152118/DJT-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27152118/DJT-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27152118/DJT-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Scientifically, discrete events can be segregated into distinct categories, which can then serve as the basis for past analogs when conducting probabilistic analysis. With this framework, when the 2-8-D sequence flashes, the following week's price action has a 60% chance of upside, with a median return of 1.7%. Should the bulls maintain control of the market, DJT stock could see an 8.06% move in the second week.
<h2 class="wp-block-heading">A Tempting Offer On The Table</h2>
With the poor performance of DJT stock on Friday, market makers are in a giving mood. Subsequently, the 17.50/18.00 bull call spread expiring July 25 may represent a tempting idea. This transaction involves buying the $17.50 call and simultaneously selling the $18 call, for a net debit paid of $23 (the most that can be lost in the trade). Should DJT rise through the short strike price ($18) at expiration, the maximum reward is $27, a payout of over 117%.
This trade is enticing because you're given about four weeks for DJT stock to rise 4.4%. Based on past responses to the 2-8-D sequence, this is a realistic target. Further, as a baseline, the chance that DJT will rise over any given week is only 45.41%. However, past analogs demonstrate that investors historically buy the dips, making the current profile attractive.
Without converting continuous price signals into a binary code, I wouldn't be able to determine the probability of upside other than resorting to a trust-me-bro assertion. Combined with the fundamental speculation and the technical heuristics, the math seems to favor DJT stock. It's still a wildly risky wager but this way, you can gamble your "fun money" strategically and intelligently.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/06/46127885/intc-stock-intel-china-restrictions-geopolitics">Options Corner: Intel Hides In Plain Sight Amid The Shifting Geopolitical Spotlight</a></li>
</ul>
Photo: Shutterstock

Equities

Long Ideas

Options

Options Corner: Trump Media Might Rally As Political Wins Stack Up

Federal Reserve

Live On CNBC, U.S. Secretary of the Treasury Scott Bessent Says Powell Doesn't Have To Leave Fed, He Can Stay On The Board But Not As Chair

Pennsylvania American Water to Invest Over $5 Million in First Five Years
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.amwater.com%2Fpaaw%2F&amp;esheet=54283289&amp;newsitemid=20250627925095&amp;lan=en-US&amp;anchor=Pennsylvania+American+Water&amp;index=1&amp;md5=f0f36c36dc87ec60af03eca6f5a393e1">Pennsylvania American Water</a> announced today that it signed an agreement with the City of Pittston to acquire its wastewater collection system for $26.4 million. The system serves approximately 4,400 customers throughout the city. Pennsylvania American Water is already the drinking water service provider for the City of Pittston and has more than 135,000 customer connections in the region.
As part of the agreement, Pennsylvania American Water has agreed to make necessary collection system upgrades, which are expected to total more than $5.1 million over five years. Specifically, the company plans to make significant investments in main replacements; technology updates; security and safety systems; and geographic information system improvements.
Pennsylvania American Water will seek all necessary approvals from its regulators and expects to close the transaction by late 2026.

Pennsylvania American Water Agrees With City Of Pittston To Acquire Its Wastewater Collection System For $26.4M

Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) has outperformed the market over the past 10 years by 3.4% on an annualized basis producing an average annual return of 14.88%. Currently, Intercontinental Exchange has a market capitalization of $104.43 billion. 
Buying $1000 In ICE: If an investor had bought $1000 of ICE stock 10 years ago, it would be worth $4,025.65 today based on a price of $181.75 for ICE at the time of writing.
<h3>Intercontinental Exchange's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751055312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Live On CNBC, U.S. Secretary of the Treasury Scott Bessent Says Natural For Currencies To Move Around; Currencies Move Up And Down, U.S. Still Has Strong Dollar Policy

<a href="https://www.theinformation.com/articles/google-convinces-openai-use-tpu-chips-win-nvidia" title="https://www.theinformation.com/articles/google-convinces-openai-use-tpu-chips-win-nvidia">https://www.theinformation.com/articles/google-convinces-openai-use-tpu-chips-win-nvidia</a>

MSFT

NVDA

'Google Convinces OpenAI To Use TPU Chips In Win Against Nvidia' - The Information

Shares of Alphabet are trading higher following the Russell index's annual reconstitution and rebalancing, which takes place annually at the end of June.

Live On CNBC, U.S. Secretary of the Treasury Scott Bessent Says We Believe That Rare Earth Magnets Are Starting To Flow Again With China; When We Are Certain, We Will Drop Countermeasures; 20 Countries That Could Go Back To Reciprocal Tariffs, Or If We Think Negotiating In Good Faith They Could Stay At 10%

Shares of Amazon are trading higher following the Russell index's annual reconstitution and rebalancing, which takes place annually at the end of June.

PLTR

Shares of Palantir are trading lower. The stock may be down following investor concerns about the company's valuation, as well as profit-taking from traders.

Live On CNBC, U.S. Secretary of the Treasury Scott Bessent Says As Of Monday, Canada Will Introduce A Retroactive Tax; My Inclination Is That USTR Will Start A 301 Investigation Into Digital Services Taxes; Think About $2B Retroactive Digital Service Taxes From Canada

Bexotegrast development in IPF discontinued
Clinical oncology program and early-stage programs continue
Recent workforce and operational changes align with next steps
SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF).
BEACON-IPF Trial Update
BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of BEACON-IPF following a prespecified data review and recommendation by the trial's independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, citing an imbalance in IPF-related adverse events.
Following an analysis of the full safety and efficacy data from the BEACON-IPF trial, the Company is discontinuing development of bexotegrast in IPF. Results showed that at doses of 160 mg and 320 mg, bexotegrast demonstrated an unfavorable risk-benefit profile. Compared to placebo, bexotegrast-treated participants showed an increased risk of experiencing adverse events associated with IPF disease progression, defined as events of worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality. The average time to disease progression for bexotegrast-treated participants was 33 weeks, suggesting that the safety risk may not be apparent with shorter dosing duration as was the case in the prior INTEGRIS-IPF Phase 2a trial.&nbsp;
At Week 12, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in forced vital capacity (FVC) decline of 72 mL (p&lt;0.05) and 46 mL (p&gt;0.05), respectively, compared to placebo. At Week 24, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in FVC decline of 58 mL (p&gt;0.05) and 8 mL (p&gt;0.05), respectively, compared to placebo.
The full results from BEACON-IPF will be submitted for future publication.
Oncology Phase 1 Enrollment Continues
PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, designed to block TGF-β activation in the tumor microenvironment. PLN-101095 is currently undergoing a Phase 1 open-label trial as monotherapy and in combination with pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. In March, the Company announced interim results from this trial showing that PLN-101095 was generally well tolerated with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types. The trial is currently enrolling the fifth of five planned dose cohorts.
Early Programs Supported by Proprietary Platform
The Company's drug discovery platform consists of a proprietary library of over 15,000 integrin binding molecules, a comprehensive screening assay system (binding, integrin confirmation, ligand-induced internalization) and an advanced live human tissue program. The Company believes in the broad applicability of the platform across multiple disease areas including delivery of drug payloads to cells utilizing integrin receptor-binding molecules as tissue-specific delivery and internalization mechanisms.

Pliant Therapeutics Discontinues Development Of Bexotegrast In Idiopathic Pulmonary Fibrosis After BEACON-IPF Phase 2b/3 Clinical Trial Review

Wall Street returned to record highs at the end of June, with both the S&amp;P 500 and Nasdaq 100 breaking above their February peaks, capping a powerful rebound from <a href="https://www.benzinga.com/markets/economic-data/25/06/46124290/sp-500-hits-record-highs-and-history-says-the-best-is-yet-to-come">April's tariff-driven lows.</a>
Investor sentiment turned positive as geopolitical and trade risks eased. Oil prices slumped $12 to $65 after a symbolic Iranian strike on a U.S. base in Qatar failed <a href="https://www.benzinga.com/markets/25/06/46101460/oil-was-supposed-to-soar-on-iran-strikes-it-just-crashed-instead">to escalate tensions further. </a>
President Donald Trump announced that a ceasefire between Israel and Iran had been established, effectively ending the 12-day conflict.
During his two-day testimony before Congress, Federal Reserve Chair Jerome Powell said this year's tariff hikes are likely to raise prices and weigh on the economy, warranting caution <a href="https://www.benzinga.com/markets/economic-data/25/06/46077396/powell-interest-rates-trump-inflation-tariffs">on interest rate cuts.</a>
Powell's neutral tone sparked renewed friction with President Trump, who continues to criticize the Fed chair and fuel speculation over a possible leadership change when Powell's term <a href="https://www.benzinga.com/news/25/06/46115346/trump-powell-fed-chairman-odds-dollar">ends in May 2026</a>.
Markets now anticipate that Trump's influence could lead to a more dovish pivot at the central bank. Traders are pricing in two rate cuts before year-end and persistent dollar weakness, with the U.S. Dollar Index falling to levels last seen in February 2022—before Russia's invasion of Ukraine—and heading for its worst <a href="https://www.benzinga.com/markets/economic-data/25/06/46146713/trump-dollar-outlook-tariffs-debt">half-year since 1991.</a>
The stock rally gained momentum at the end of the week as Commerce Secretary Howard Lutnick said the U.S. reached a trade agreement with China. Officials also signaled progress in trade talks with at least 10 other countries, suggesting a softening stance from the White House toward protectionist policies.
In corporate news, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) surged to new record highs, reaching a market <a href="https://www.benzinga.com/content/46149573/nvidias-stock-price-hits-new-highs-this-is-whats-next">capitalization of $3.85 trillion. </a>
The AI-chip giant reclaimed the title of the world's most valuable publicly traded company, overtaking Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) once again amid continued dominance in the AI chip market. 
On Friday, Trump announced an abrupt halt to all trade negotiations with Canada, a key U.S. trading partner, due to a Digital Services Tax on U.S. corporations. The move halted the market&#8217;s strong gains during the session and raised investor anxiety ahead of July&#8217;s 9 tariff deadline.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46150909/trump-canada-tariffs-dollar-deal">Trump Flips On Canada Trade Deal, Sending Shivers Through Wall Street</a> </li>
</ul>
Image created using artificial intelligence via Midjourney.

Government

Regulations

Tech

Wall Street Soars To Record Highs, Nvidia Becomes World's Most Valuable Company: This Week In Markets

System1 May Offer, Sell Up To $250M In Aggregate Of Class A Common Stock From Time To Time

The AZEK Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) ("AZEK" or the "Company"), the industry-leading manufacturer of beautiful, low-maintenance and environmentally sustainable outdoor living products, including TimberTech&#xAE; Decking and Railing, AZEK&#xAE; and Versatex&#xAE; Trim and StruXure&#xAE; pergolas, today announced that its stockholders have voted to approve all proposals related to the Company's proposed transaction with James Hardie Industries plc ("James Hardie") at its Special Meeting of Stockholders. As previously announced, under the terms of the merger agreement and subject to the completion of the transaction, AZEK stockholders will receive $26.45 in cash and 1.0340 ordinary shares of James Hardie to be listed on the New York Stock Exchange for each share of AZEK common stock owned.
The transaction is expected to close on or about July 1, 2025, subject to the satisfaction or waiver of the closing conditions set forth in the merger agreement.
Approximately 99.96% of the votes cast at the Special Meeting voted in favor of the proposal to adopt the merger agreement, representing approximately 75.78% of AZEK's total outstanding shares of common stock. The final vote results, as certified by the inspector of elections, will be filed on a Form 8-K filed with the U.S. Securities and Exchange Commission. &nbsp;

AZEK

AZEK Stockholders Approve Merger With James Hardie; Holders To Receive $26.45 Cash, 1.0340 Shares Per AZEK Share

Sports

Press Releases

Inaugural College Basketball Crown Releases Ticket & Television Schedule

We're (SUPER) Sorry for your Team's Loss: Vivid Seats and The Bouqs Co. Launch Consolation Contest

Vivid Seats to Report Fourth Quarter and Full Year 2024 Financial Results

Vivid Seats Releases Inaugural 2025 MLB Fan Loyalty Report

Earnings

Vivid Seats Reports Fourth Quarter and Full Year 2024 Results

[Corrected Press Release] Vivid Seats Reports Fourth Quarter and Full Year 2024 Results

Vivid Seats Debuts 2025 Trending Music Festival Guide

Vivid Seats to Report First Quarter 2025 Financial Results

Vivid Seats Reports First Quarter 2025 Results

Vivid Seats Announces 2025 WNBA Loyalty Report

SEATW

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Entertainment Hldgs

Anghami

Atlanta Braves Holdings, Inc. - Series C Common Stock

Atlanta Braves Holdings

Cineverse

CuriosityStream Inc. - Class A Common Stock

CuriosityStream

Eventbrite

Gaia

Global Mofy AI Limited - Class A Ordinary Shares

Global Mofy AI

iQIYI

Kuke Music Holding Limited American Depositary Shares (each representing ten (10) Class A Ordinary Shares)

Comments

Vivid Seats

뉴스

파트너 / 기고자

벤징가 글로벌